Table 2 Geometric mean ratio, geometric mean fold increase, and seroconversion and 95% CI of specific antibody responses (AUC) to S1, RBD, and neutralizing antibody titer in the BBIBP-CorV and RCP groups over the predefined study time schedule
| Â | Neutralizing antibody titera | Anti-SARS-CoV-2 S1 IgG levelb AUCc | Anti-SARS-CoV-2 RBD IgG levelAUC | |||
|---|---|---|---|---|---|---|
BBIBP-CorV | RCP | BBIBP-CorV | RCP | BBIBP-CorV | RCP | |
GMFI (95% CI)e | ||||||
Baseline | Ref | Ref | Ref | Ref | Ref | Ref |
 Day 14 | 2.77 (2.26–3.39) | 21.51 (16.35–28.32) | 4.41 (3.66–5.32) | 15.66 (12.58–19.16) | 4.33 (3.58–5.25) | 18.22 (14.66–22.64) |
 Day 90 | 48.62 (29.27–80.77) | 90.22 (48.98–166.18) | 4.92 (3.27–7.44) | 8.37 (4.86–13.20) | 5.39 (3.55–8.18) | 9.34 (5.65–15.45) |
 Day 180 | 28.02 (17.18–45.72) | 83.08 (45.75–150.91) | 4.18 (2.74–6.37) | 7.05 (4.13–12.04) | 4.35 (2.84–6.66) | 7.23 (4.17–12.51) |
GMR (95% CI)f | ||||||
 Baseline | Ref | 0.88 (0.63–1.22) | Ref | 0.92 (0.70–1.21) | Ref | 0.90 (0.68–1.19) |
 Day 14 | Ref | 6.81 (5.32–8.72) | Ref | 3.17 (2.73–3.70) | Ref | 3.67 (3.14–4.30) |
 Day 90 | Ref | 1.77 (1.15–2.72) | Ref | 2.03 (1.57–2.64) | Ref | 2.20 (1.65–2.94) |
 Day 180 | Ref | 2.37 (1.62–3.47) | Ref | 1.73 (1.35–2.21) | Ref | 1.81 (1.38–2.39) |
Seroconversion, n/N (95% CI)g | ||||||
 Day 14 | 69/211, 33% (26–39) | 157/202, 78% (71–83) | 99/202, 49% (42–56) | 152/195, 78% (72–83) | 100/202, 49% (42–56) | 157/195, 80% (74–850) |
 Day 90 | 55/59, 93% (84–98) | 39/42, 93% (80–98) | 29/59, 49% (36–61) | 25/41, 60% (45–75) | 32/59, 54% (41–66) | 25/41, 60% (44–75) |
 Day 180 | 42/48, 87% (75–95) | 36/37, 97% (85–99) | 24/48, 50% (36–64) | 24/38, 63% (48–78) | 25/48, 52% (38–66) | 23/38, 61% (45–76) |